BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

U.K.-based NodThera is building up the company’s war chest to develop therapies for diseases driven by chronic inflammation, securing $55 million in Series B financing.

Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.

Gotham Therapeutics launched in New York with a $54 million Series A financing. The round was co-led by founding investor Versant Ventures, Forbion, and S.R. One.

Magnolia Neurosciences, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.

Akouos, a precision genetic medicine company developing gene therapies that restore and preserve hearing, today announced that the company raised $50 million in Series A financing.

Cambridge, Mass.-based HotSpot Therapeutics burst forth from stealth mode with $45 million in Series A funding to support the development of therapies that will target natural “regulatory hotspots.”

Verge Genomics, a drug discovery company that uses artificial intelligence and machine learning to develop new therapeutics, secured $32 million in a Series A financing round to accelerate its drug discovery programs.

Chinese companies and investors continue to flex their financial muscles with a series of deals that highlight the continued growing impact that country is having on the global pharmaceutical and biotech landscape.